1.85
-0.02(-1.07%)
Currency In USD
| Previous Close | 1.87 |
| Open | 1.83 |
| Day High | 1.89 |
| Day Low | 1.8 |
| 52-Week High | 62.16 |
| 52-Week Low | 1.71 |
| Volume | 17,182 |
| Average Volume | 2.17M |
| Market Cap | 1.67M |
| PE | -0.01 |
| EPS | -250.62 |
| Moving Average 50 Days | 2.4 |
| Moving Average 200 Days | 9.43 |
| Change | -0.02 |
If you invested $1000 in Nuwellis, Inc. (NUWE) 10 years ago, it would be worth $0 as of February 21, 2026 at a share price of $1.85. Whereas If you bought $1000 worth of Nuwellis, Inc. (NUWE) shares 5 years ago, it would be worth $0 as of February 21, 2026 at a share price of $1.85.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Nuwellis Appoints Carisa Schultz as Chief Financial Officer
GlobeNewswire Inc.
Jan 30, 2026 1:00 PM GMT
Schultz brings public company healthcare finance and medical technology experience to support Nuwellis’ next phase of growthMINNEAPOLIS, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE) a medical technology company focused on advanci
Nuwellis Announces $5 Million Private Placement and Warrant Inducement Transaction, Priced At-The-Market
GlobeNewswire Inc.
Jan 29, 2026 9:36 PM GMT
MINNEAPOLIS, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE) (“Nuwellis” or the “Company”), a medical technology company focused on advancing precision cardiorenal care in critical care settings, today announced that it has entered
Nuwellis Enters into Definitive Agreement to Acquire Rendiatech, Advancing Its Cardiorenal Portfolio Strategy
GlobeNewswire Inc.
Jan 29, 2026 9:35 PM GMT
Transaction positions Nuwellis to expand into real-time kidney function monitoring and strengthen its long-term cardiorenal platform, subject to customary closing conditionsMINNEAPOLIS, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE